Cellebrite DI Ltd. (CLBT)
UndervaluedFundamental
66
मूल्य
$11.26
मार्केट कैप
$2.83B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Cellebrite DI Ltd. is an Israeli software company that sells digital investigation tools to law enforcement, prosecutors, defence and intelligence agencies, and to a smaller extent to corporate and private-sector investigators. Its products let an authorised investigator lawfully access a locked mobile phone, computer, cloud account or other digital source, extract the data, then review, analyse and share it in a form that can be used as evidence. The portfolio spans device access and extraction, analytics that connect evidence across many devices in one case, and case-management software that lets an agency share findings with prosecutors; it is complemented by lab-based advanced access services, training and certification. In fiscal 2025 the company reported total revenue of $475.7 million, and the filing states that more than 90% of revenue in 2023, 2024 and 2025 came from public-sector customers.
यह पैसा कैसे कमाती है
Cellebrite sells mostly through annual and multi-year subscription agreements rather than one-off licences. The filing splits revenue into four lines. Subscription services — cloud and hosted software billed over the term — were $330.8 million in fiscal 2025 and are recognised over the life of the subscription. Term licences — on-premise subscription licences — were $96.2 million and are recognised immediately at the point of sale. Together these two lines make up what the company calls subscription revenue, $427.0 million in 2025, up 21% on 2024. Professional services (advanced access work performed in Cellebrite's own labs, training and consulting) were $30.9 million, and other non-recurring revenue, which includes hardware, was $17.8 million. Two consequences matter for a reader: the company itself notes that a subscription model makes it hard to grow reported revenue quickly, because new business is spread across the contract term; and the upfront recognition of term licences can make individual quarters lumpy even when the underlying contract base is stable.
प्रतिस्पर्धी बढ़त (Moat)
पेटेंट और लाइसेंस · संकीर्णThe difficult, repeatable thing Cellebrite does is re-engineer lawful access to devices whose makers keep hardening encryption and locking down operating systems. That is a research capability — proprietary methods, a large accumulated body of device and app knowledge, and the staff who maintain it — that very few firms can fund and sustain year after year. Around it sit softer but real frictions: evidence produced by the tool has to stand up in court, examiners are trained and certified on it, and the software is embedded in agency workflows and government purchasing vehicles, so switching is disruptive rather than merely inconvenient. The advantage is narrow rather than wide because competitors exist in the same niche, and because a phone maker closing a method can erase part of the capability at any time — the filing itself lists keeping pace with technological change and intense competition among its principal risks.
मांग को क्या चलाता है
डिफेंसिवDemand is driven by the volume of digital evidence in ordinary casework rather than by the economic cycle: crimes are investigated, and phones and cloud accounts are part of nearly every case, whether the economy is expanding or contracting. Police, prosecution and intelligence budgets are among the last public expenses to be cut, which makes the underlying demand defensive. The qualification is timing rather than direction: the company's own risk factors point to government budgeting cycles, appropriations uncertainty, spending reductions and long sales cycles for larger transactions, so orders can slip between quarters or years even when the need has not changed.
प्रमुख जोखिम
- Dependence on government and law-enforcement buyers — The company states that its business depends materially on the purchase, acceptance and use of its solutions by law enforcement and government agencies, and that more than 90% of revenue in 2023, 2024 and 2025 came from public-sector customers. Government contracts bring budgeting cycles, appropriations uncertainty, termination rights and the risk of spending reductions.
- Keeping pace with technological change — Cellebrite lists its ability to keep pace with technological advances and evolving industry standards as a principal risk. Its access capabilities must be rebuilt continuously as device manufacturers and operating-system vendors change their security.
- Renewal of subscriptions — Because the business is sold on annual and multi-year subscriptions, the filing identifies dependence on customers renewing those subscriptions as a specific risk; revenue is not secured beyond the contract term.
- Errors, defects or bugs in the solutions — The company flags real or perceived errors, failures, defects or bugs in its digital investigation solutions as a risk. Output used as evidence is held to a higher standard than ordinary software output, so a defect can carry legal as well as commercial consequences.
- Misuse of the solutions and reputational harm — Among its risk factors the company includes misuse of its solutions by customers and the negative publicity and reputational harm that can follow. Tools designed for lawful investigation can be deployed in ways that draw public and regulatory scrutiny.
- Competition and consolidation — The filing lists intense competition and market consolidation among its risks, alongside dependence on technology licensed from third parties and on retaining sales and marketing personnel.
- Artificial intelligence and currency exposure — The company names risks tied to implementing artificial intelligence in its products, and foreign-currency exposure: the filing notes that a substantial share of its expenses — around 32% — is denominated in Israeli shekels while revenue is largely in dollars. Geopolitical instability affecting its Israeli operations is also disclosed.
ग्राहक Concentration
The filing does not disclose a combined share for a set number of largest customers, so no figure is given here. What it does disclose is concentration by customer type: public-sector customers were more than 90% of revenue in 2023, 2024 and 2025, and U.S. federal government customers alone were approximately 16% of 2025 revenue. The practical reading is that the risk is not one large account walking away but a whole class of buyer — government agencies, and in particular the U.S. federal budget — moving together.
खरीदने के पक्ष में तर्क
Buyers argue that the amount of digital evidence per case keeps rising while agencies remain short of examiners, so the work Cellebrite automates is needed regardless of the economic cycle. They point to a revenue base that is now overwhelmingly subscription — $427.0 million of the $475.7 million reported for 2025, growing 21% — sold to public agencies that renew rather than shop around, and to the long shift of the installed base from one-off tools and hardware towards recurring software. They also argue that the company is widening from device access into analysis, case management and cloud and endpoint data, which raises the value of each agency relationship, and that the underlying research capability is very hard for a new entrant to replicate.
बेचने के पक्ष में तर्क
Sellers fear that a company taking more than 90% of its revenue from public agencies has no second leg to stand on when budgets tighten: the filing itself lists government budgeting cycles, appropriations uncertainty, termination rights and spending reductions, and U.S. federal customers alone were about 16% of 2025 revenue. They fear the technology side is a permanent arms race the company can lose — device makers keep hardening encryption, and the filing names keeping pace with technological change as a principal risk. They also point to the reputational and regulatory exposure the company discloses around customer misuse of its tools, to competition and consolidation in a narrow niche, and to the mechanics of the accounts: term licences recognised upfront can flatter or depress a quarter, and roughly 32% of expenses sit in shekels against dollar revenue, on top of the geopolitical risk of concentrating operations in Israel.
Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users
Direct competitors
Who this company fights with for the same customers
Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users
Sells the AXIOM investigation platform and the GrayKey mobile extraction tool to the same police forces, prosecutors and government agencies that buy Cellebrite's UFED and Inseyets.
Its XRY extraction and XAMN analysis products cover the same mobile-forensics workflow for law enforcement in over 100 countries, and it bids for the same public-sector contracts.
Oxygen Forensic Detective extracts and analyses data from phones, cloud accounts and drones for the same investigative agencies, and is often the cheaper alternative in the same tenders.
Through the former AccessData line (FTK) it sells digital forensics and e-discovery software to law enforcement and corporate investigation teams, the same buyers Cellebrite targets with its enterprise offering.
Its EnCase Forensic and Endpoint Investigator products compete for the computer- and enterprise-side budget of the same police and corporate investigation units.
Nuix Neo processes and analyses seized digital evidence for police, regulators and corporate investigators, overlapping with Cellebrite's review and analytics tier rather than with device extraction.
बैलेंस शीट और तरलता
राजस्व
$514M
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$59M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$125M
कुल इक्विटी
$539M
कुल देनदारियाँ
$23M
Current Ratio
1.62
Interest Coverage
-
Debt/EBITDA
0.30
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$19.86
वर्तमान मूल्य
$11.26
Margin of Safety
+43.3%
Fair Value सीमा
$12.91 - $26.81
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
48.96
ROE
12.4%
P/B Ratio
5.25
P/FCF
22.65
Gross Margin
83.0%
ROIC
3.8%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
3.8%
WACC
10.3%
ROIC − WACC
-6.5 pp
ROIC पूंजी की लागत से कम है — कंपनी निवेशित हर डॉलर पर मूल्य नष्ट कर रही है।
Fundamental विश्लेषण मानदंड
पास (13)
- Gross Margin 83.0%
- P/FCF 22.65
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- ROE 11.9%
- Revenue Growth 5Y 19.5%
- Analyst Consensus 93% Buy
- Earnings Surprise avg 6.8%
- PEG Ratio 0.82
- Earnings Quality (OCF/NI) 2.01
- Net Margin Trend 16.5% vs -70.5%
फेल (6)
- Price CAGR 1.48%
- ROIC 3.8%
- P/B Ratio 5.25
- CapEx intensity
- DCF valuation (Overvalued)
- Piotroski F-Score 2/9
अनुपलब्ध (8)
- EPS data insufficient
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Share Dilution (missing shares data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
इस कंपनी के लिए कोई संस्थागत घोषणा उपलब्ध नहीं है।
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. David Barter | Chief Financial Officer | 53 |
| Mr. Thomas E. Hogan | Advisor | 66 |
| Mr. Marcus Jewell | Global Chief Revenue Officer | 52 |
| Mr. Shiven Ramji | CEO & Director | - |
| Mr. Christopher Wade | Chief Technology Officer | 41 |
| Ms. Sigalit Shavit | Chief Information Officer | 57 |
| Andrew Kramer | VP of Investor Relations & Treasury | - |
| Ms. Holly B. Windham Esq., J.D. | General Counsel & Chief Compliance Officer | 58 |
| Mr. David Nicholas Gee | Chief Marketing Officer | 58 |
| Ms. Zohar Tadmor-Eilat | Chief People Officer | 53 |
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for CLBT, sourced from Markets Gazette.